MedTrace Logo

Effect of Policosanol as Monotherapy and Adjunctive to Statin Therapy

NCT00510809 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2015-10-08

Study results available
· View outcomes & findings →

Summary

To determine the effects of policosanol on the cholesterol profile.

Conditions

Interventions

DRUG

Policosanol

Policosanol 20 mg daily

OTHER

Placebo

Placebo daily

DRUG

Policosanol Plus Already In Use Statin Therapy

Policosanol 20 mg daily Statin Therapy

Sponsors & Collaborators

  • Marcor Development Corporation

    collaborator UNKNOWN

  • James Backes, PharmD

    lead OTHER

Principal Investigators

  • James M. Backes, PharmD · University of Kansas Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2010-03-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00510809 on ClinicalTrials.gov